 | | Vol. 14.29 – 1 August, 2023 |
| |
|
|
| Independent predictors of sustained stabilization were the change in beta-cell function during induction, and changes in hepatic insulin resistance and alanine aminotransferase during maintenance.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Investigators showed that factor(s) derived from β cells stimulated platelet activity and platelets selectively localized to the vascular endothelium of pancreatic islets.
[EMBO Molecular Medicine] |
|
|
|
| The lack of Hpa2 was associated with a marked decrease in the expression of key pancreatic transcription factors such as PTF1, GATA6, and Mist1.
[Cell Death & Disease] |
|
|
|
| The glucose dependent inhibition of glucagon secretion relies on pyruvate dehydrogenase and carnitine palmitoyl transferase 1a activity and lowering of mitochondrial fatty acid oxidation by increases in glucose.
[Diabetes] |
|
|
|
| Researchers found that verapamil reduced beta-cell expression of IGF-binding protein 3 (IGFBP3), whereas IGFBP3 was increased in human islets exposed to type 1 diabetes-associated cytokines and diabetic NOD mouse islets.
[Diabetes] |
|
|
|
| To investigate the role of Reg family proteins in chronic pancreatitis, scientists generated global knockout mice for regenerating genes (Reg) 1-3 using the CRISPR/Cas9 system.
[Scientific Reports] |
| |
|
|
| In vitro and in vivo assays demonstrated that Schwann cells enhanced the proliferation and migration of PDAC cells via Midkine signaling, and promoted the switch of cancer-associated fibroblasts (CAFs) to basal-like and inflammatory CAFs via interleukin-1α.
[Nature Communications] |
|
|
|
| Proteomic analysis was performed to compare changes of Panc02 cell lines cultured with conditional medium and leucine rich repeat kinase 2 was identified as a differential gene.
[Molecular Therapy] |
|
|
|
| Various clinicopathologic factors, including the tumor size, tumor location, clinical stage, histologic subtype, and tumor differentiation, did not influence the patient-derived organoid establishment.
[Digestive Endoscopy] |
|
|
|
|
| T cells engineered with mutant (m)KRAS-specific T cell receptors have already shown early clinical promise, and next-generation mKRAS vaccines are being studied. As this emerging field rapidly develops, scientists suggest that a significant component in ‘drugging KRAS’ may be immunological.
[Trends In Cancer] |
|
|
|
| The authors focus on the causes and implications of β-cell failure, as well as its potential reversibility as a type 2 diabetes treatment.
[Experimental & Molecular Medicine] |
|
|
|
|
| Elraglusib is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta inhibitor which is being developed for adults and children with advanced refractory cancers.
[Actuate Therapeutics] |
|
|
|
|
| September 28 – 30, 2023
New York, New York, United States |
|
|
|
|
|
| | IRB Barcelona – Barcelona, Spain |
|
|
|
| | Max Planck Institute – Dresden, Germany |
|
|
|
| | University of Oklahoma – Oklahoma City, Oklahoma, United States |
|
|
|
| | Rutgers Cancer Institute of New Jersey – New Brunswick, New Jersey, United States |
|
|
|
| | Joslin Diabetes Center – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
